

## **Bernhard Ludvik, M.D.**

Associate Professor of Medicine  
Medical University of Vienna

### **BIBLIOGRAPHY**

#### **ORIGINAL PAPERS AND REVIEWS**

1. Hartter E, Weissel M, Stummvoll HK, Woloszczuk W, Punzengruber C, **Ludvik B**: Atrial natriuretic peptide concentrations in blood from right atrium in patient with severe right heart failure. *Lancet* 2:93-94, 1985
2. Weissel M, Punzengruber C, Hartter E, **Ludvik B**, Woloszczuk W: Thyroid hormones and pericardial effusion may influence plasma levels of atrial natriuretic peptide (ANP) in humans. *Klin.Wochenschr.* 64 Suppl 6:93-96, 1986
3. Woloszczuk W, **Ludvik B**: Nachweis und radioimmunologische Quantifizierung von humanem atrialen natriuretischen Peptid im Harn. *Berichte der ÖGKC* 9:65-67, 1986
4. Punzengruber C, Hartter E, Weissel M, Burghuber OC, **Ludvik B**, Woloszczuk W: [Peripheral and right atrial plasma levels of atrial natriuretic peptide and their relation to mean atrial pressure]. *Z.Kardiol.* 76:72-75, 1987
5. **Ludvik B**, Niederle B, Roka R, Schernthaner G, Neuhold N: [Malignant aldosteronoma in the differential diagnosis of Conn syndrome]. *Acta Med.Austriaca* 15:117-120, 1988
6. Hay U, **Ludvik B**, Gisinger C, Schernthaner G: [Lack of effect of ACE inhibition on severe proteinuria in diabetic nephropathy--a 6-month-long study]. *Schweiz.Med.Wochenschr.* 118:165-169, 1988
7. Wrba F, Chott A, **Ludvik B**, Schratte M, Spona J, Reiner A, Schernthaner G, Krisch K: Solid and cystic tumour of the pancreas; a hormonal-dependent neoplasm? *Histopathology* 12:338-340, 1988
8. Wrba F, Chott A, Schratte M, **Ludvik B**, Krisch K, Holzner JH: [Fine-needle puncture cytology of a solid cystic tumor of the pancreas]. *Pathologe* 9:340-344, 1988
9. **Ludvik B**, Scheithauer W, Wrba F, Schratte M, Schiessel R, Schernthaner G: [Gestagen receptor-positive, solid-cystic acinar-cell tumor of the pancreas]. *Dtsch.Med.Wochenschr.* 114:903-906, 1989
10. Hartter E, Svoboda T, Lell B, Schuller M, **Ludvik B**, Woloszczuk W, Prager R: Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus. *Lancet* 335:854, 1990
11. Graf H, Watzinger U, **Ludvik B**, Wagner A, Hocker P, Zweymuller KK: Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. *BMJ* 300:1627-1628, 1990
12. **Ludvik B**, Kueenburg E, Brunnbauer M, Schernthaner G, Prager R: The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. *J.Cardiovasc.Pharmacol.* 18 Suppl 2:S157-S159, 1991
13. Prager R, **Ludvik B**, Hartter E: [Role of amylin in the pathogenesis of type II diabetes mellitus]. *Acta Med.Austriaca* 18:61-62, 1991

14. **Ludvik B**, Peer G, Berzlanovich A, Stifter S, Graf H: Effects of dichloroacetate and bicarbonate on haemodynamic parameters in healthy volunteers. *Clin.Sci.(Colch.)* 80:47-51, 1991
15. Hartter E, Svoboda T, **Ludvik B**, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co- secretion with insulin in humans. *Diabetologia* 34:52-54, 1991
16. **Ludvik B**, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. *Diabetes* 40:1615-1619, 1991
17. **Ludvik B**, Kautzky-Willer A, Prager R: Epidemiologie: Ätiologie und neue therapeutische Konzepte bei Adipositas. *Therapiewoche Österreich* 7:14-19, 1992
18. Kautzky-Willer A, Pacini G, **Ludvik B**, Schernthaner G, Prager R: Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects. *Metabolism* 41:1304-1312, 1992
19. **Ludvik B**, Niederle B, Roka R, Neuhold N, Templ M, Schernthaner G: Isolated primary hyperaldosteronism in adrenocortical carcinoma. *Acta Chirurgica Austriaca* 25:212-216, 1993
20. **Ludvik B**, Stifter S, Hartter E, Capek M, Prager R, Graf H: Accresciuti livelli del polipeptide amiloide delle isole non hanno effetto sulla secrezione di insulina in pazienti con danno renale cronico. *Giornale italiano di Diabetologia* 12:204-205, 1993
21. **Ludvik B**, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. *Diabetologia* 36:84-87, 1993
22. Kautzky-Willer A, Pacini G, Weissel M, Capek M, **Ludvik B**, Prager R: Elevated hepatic insulin extraction in essential hypertension. *Hypertension* 21:646-653, 1993
23. **Ludvik B**, Mayer G, Stifter S, Putz D, Barnas U, Graf H: Effects of dichloroacetate on exercise performance in healthy volunteers. *Pflugers Arch.* 423:251-254, 1993
24. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, **Ludvik B**, Strelci C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. *Diabetologia* 37:188-194, 1994
25. **Ludvik B**, Clodi M, Kautzky-Willer A, Schuller M, Graf H, Hartter E, Pacini G, Prager R: Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. *J.Clin.Invest* 94:2045-2050, 1994
26. Nolan JJ, **Ludvik B**, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. *N.Engl.J.Med.* 331:1188-1193, 1994
27. Capek M, Schnack C, **Ludvik B**, Kautzky-Willer A, Banyai M, Prager R: Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. *Clin.Investig.* 72:961-966, 1994
28. Kautzky-Willer A, Pacini G, Barnas U, **Ludvik B**, Strelci C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. *Kidney Int.* 47:200-206, 1995
29. **Ludvik B**, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. *J.Clin.Invest* 95:2232-2238, 1995
30. **Ludvik B**, Nolan JJ, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. *Diabetes* 44:1121-1125, 1995

31. Kotzmann H, Linkesch M, **Ludvik B**, Clodi M, Luger A, Schernthaner G, Prager R, Klauser R: Effect of danazol-induced chronic hyperglucagonaemia on glucose tolerance and turnover. *Eur.J.Clin.Invest* 25:942-947, 1995
32. Thomaseth K, Kautzky-Willer A, **Ludvik B**, Prager R, Pacini G: Integrated mathematical model to assess beta-cell activity during the oral glucose test. *Am.J.Physiol* 270:E522-E531, 1996
33. Kautzky-Willer A, Thomaseth K, Clodi M, **Ludvik B**, Waldhausl W, Prager R, Pacini G: Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. *Metabolism* 45:486-491, 1996
34. Kautzky-Willer A, Thomaseth K, **Ludvik B**, Nowotny P, Rabensteiner D, Waldhausl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. *Diabetes* 46:607-614, 1997
35. Nolan JJ, **Ludvik B**, Baloga J, Reichart D, Olefsky JM: Mechanisms of the kinetic defect in insulin action in obesity and NIDDM. *Diabetes* 46:994-1000, 1997
36. **Ludvik B**, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G: Amylin: history and overview. *Diabet.Med.* 14 Suppl 2:S9-13, 1997
37. Thomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R, Olefsky JM, **Ludvik B**: Amylin release during oral glucose tolerance test. *Diabet.Med.* 14 Suppl 2:S29-S34, 1997
38. **Ludvik B**: [Amylin/IAPP (islet amyloid polypeptide)--physiology and clinical significance]. *Wien.Klin.Wochenschr.* 109:379-383, 1997
39. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, Ulm M, Strelci C, **Ludvik B**: Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. *Diabetes Care* 20:1717-1723, 1997
40. **Ludvik B**, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. *J.Clin.Invest* 100:2354-2361, 1997
41. **Ludvik B**: [Weight loss by increasing energy consumption and thermogenesis]. *Acta Med.Austriaca* 25:136-137, 1998
42. Clodi M, Thomaseth K, Pacini G, Hermann K, Kautzky-Willer A, Waldhusl W, Prager R, **Ludvik B**: Distribution and kinetics of amylin in humans. *Am.J.Physiol* 274:E903-E908, 1998
43. **Ludvik B**: [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. *MMW.Fortschr.Med.* 142:27-28, 2000
44. Riedl M, **Ludvik B**, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. *Eur.J.Clin.Invest* 30:771-778, 2000
45. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, **Ludvik B**, Prager R, Waldhausl W: Increased plasma leptin in gestational diabetes. *Diabetologia* 44:164-172, 2001
46. Mari A, Pacini G, Murphy E, **Ludvik B**, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* 24:539-548, 2001
47. Tura A, **Ludvik B**, Nolan JJ, Pacini G, Thomaseth K: Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. *Am.J.Physiol Endocrinol.Metab* 281:E966-E974, 2001

48. **Ludvik B**, Mahdjoobian K, Waldhaeusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G: The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. *Diabetes Care* 25:239-40, 2002
49. Georg P, Kautzky-Willer A, Mahdjoobian K, Hofer A, Prager R, Pacini G, **Ludvik B**: Influence of metabolic control on splanchnic glucose uptake, insulin sensitivity, and the time required for glucose absorption in patients with type 1 diabetes. *Diabetes Care* 25:2042-2047, 2002
50. **Ludvik B**, Thomaseth K, Nolan, JJ, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. *Eur J Clin Invest* 33, 316-322, 2003
51. Tura A, Pacini G, Kautzky-Willer A, **Ludvik B**, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess  $\beta$ -cell function during OGTT in metabolic disorders. *Am J Physiol Endocrinol Metab* 285, E155-E162, 2003
52. **Ludvik B**, Waldhaeusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of Ipomoea batatas (Caiapo) in type 2 diabetic patients. *Metabolism* 52:875-880, 2003
53. Pichler B, **Ludvik B**: Future perspectives of pharmacotherapy of obesity. *Journal für Kardiologie* 10:427-429, 2003
54. **Ludvik B**, Neuffer B, Pacini G: Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic patients. *Diabetes Care* 27:436-440, 2004
55. Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, Maier C, Luger A, **Ludvik B**: The Impact of Laparoscopic Adjustable Gastric Banding (LAGB) on Plasma Ghrelin, Eating Behaviour and Body Weight. *Eur J Clin Invest* 34(8):549-54, 2004
56. Schindler K, **Ludvik B**: Methodische und praktische Aspekte der Bestimmung der Körperzusammensetzung [Assessment of Body Composition - methods and practical aspects]. *Wien Med Wochenschr* 154(13-14):305-12, 2004
57. Tripp B, **Ludvik B**: Medikamentöse Therapie der Adipositas [Pharmacotherapy of Obesity]. *Wien Med Wochenschr* 154(13-14):320-8, 2004
58. Bohdjalian A, Langer FB, Hoda A, Felberbauer FX, Silberhumer G, Zacherl J, Schindler K, Luger A, **Ludvik B**, Prager G: Chirurgische Therapie der Adipositas. *Wien Med Wochenschr* 154(13-14):329-33, 2004
59. Tripp B, **Ludvik B**: Neue Antiadiposita [Novel Anti-Obesity Drugs]. *Acta Medica Austriaca* 31(4):133-138, 2004
60. Cauza E, Hanusch-Enserer U, Strasser B, **Ludvik B**, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P: The Relative Benefits of Endurance and Strength Training on the Metabolic Factors and Muscle Function of People with Type 2 Diabetes Mellitus. *Arch Phys Med Rehabil* 86(8):1527-33, 2005
61. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, Schindler K, Luger A, **Ludvik B**, Prager G: Sleeve Gastrectomy and Gastric Banding: Effects on Plasma Ghrelin Levels. *Obes Surg* 15(7):1024-9, 2005
62. Cauza E, Hanusch-Enserer U, Strasser B, **Ludvik B**, Kostner K, Dunky A, Haber P: Continuous Glucose Monitoring in Diabetic Long Distance Runners. *Int J Sports Med* 26(9):774-80, 2005
63. Abrahamian H, **Ludvik B**, Scherthaner G, Prager R, Zellenka U, Knudsen L, Wascher T: Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). *Horm Metab Res* 37(11):684-9, 2005

64. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, **Ludvik B**: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. *J Clin Endocrinol Metab.* 91(4):1578-81, 2006
65. Langer FB, Bohdjalian A, Felberbauer FX, Fleischmann E, Reza Hoda MA, **Ludvik B**, Zacherl J, Jakesz R, Prager G: Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity? *Obes Surg* 16 (2):166-71, 2006
66. Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, Riener R, Zacherl J, **Ludvik B**: One year experience with Tantalus™: a New Surgical Approach to Treat Morbid Obesity. *Obes Surg* 16(5):627-34, 2006
67. Kautzky-Willer A, Tura A, Winzer C, Wagner OF, **Ludvik B**, Hanusch-Enserer U, Prager R, Pacini G: Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. *Diabetes Obes Metab* 8(5):561-7, 2006
68. Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhardt B, Luger A, Nowotny P, **Ludvik B**: Impact of Antiretroviral Therapy on Visfatin and Retinol Binding Protein 4 in HIV+ Subjects, *Eur J Clin Invest* 36(9):640-6, 2006
69. Riener R, Schindler K, **Ludvik B**: Psychosocial Variables, Eating Behavior, Depression and Binge Eating in Morbidly Obese Subjects. *Eating Behaviors* 7(4):309-14, 2006
70. Dorner T, Fodor JG, Lawrence K, **Ludvik B**, Rieder A: HDL-knowledge in the lay public: results of a representative population survey. *Atherosclerosis* 195(1):195-8, 2007
71. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, **Ludvik B**: Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. *J Clin Endocrinol Metab* 92(3):1168-71, 2007
72. Haider DG, Schindler K, Mittermayer F, Müller M, Nowotny P, Rieger A, **Ludvik B**, Wolzt M: Effect of rosiglitazone on visfatin and retinol binding protein-4 plasma concentrations in HIV-positive patients. *Clin Pharmacol Ther* 81(4):580-5, 2007
73. Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, **Ludvik B**: Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. *Diabetes Obes Metab* 9(5):761-3, 2007
74. Tripp B, **Ludvik B**: Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study. *Wien Med Wochenschr* 157(9-10):223-7, 2007 [German]
75. Anderwald C, Anderwald-Stadler M, Promintzer M, Prager G, Mandl M, Nowotny P, Bischof MG, Wolzt M, **Ludvik B**, Kästenbauer T, Pacini G, Luger A, Krebs M: The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. *Diabetes Care* 30(9):2374-80, 2007
76. Vila G, Maier C, Riedl M, Nowotny P, **Ludvik B**, Luger A, Clodi M: Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. *J Clin Endocrinol Metab* 92(10):3930-4, 2007
77. Kollmann A, Riedl M, Kastner P, Schreier G, **Ludvik B**: Feasibility of a mobile phone-based data service for functional insulin treatment of type 1 diabetes mellitus patients. *J Med Internet Res* 9(5):e36, 2007

78. **Ludvik B**, Hanefeld M, Pacini G: Improved Metabolic Control by Ipomoea (Caiapo) is Associated with Increased Adiponectin and Decreased High Sensitive C-reactive Protein and Fibrinogen Levels in type 2 diabetic subjects. *Diabetes Obes Metab* 10(7):586-92, 2008
79. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, **Ludvik B**, Silberhumer GR, Prager G, Stulnig TM: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. *Endocrinology* 149(3):1350-7, 2008
80. Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G, Wagner O, Kautzky-Willer A, **Ludvik B**, Clodi M, Luger A: Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. *J Clin Endocrinol Metab* 93(6):2307-12, 2008
81. Morak J, Schindler K, Goerzer E, Kastner P, Toplak H, **Ludvik B**, Schreier G: A pilot study of mobile phone-based therapy for obese patients. *J Telemed Telecare* 14(3):147-9, 2008
82. Langer FB, Bohdjalian A, Shakeri-Manesch S, Felberbauer FX, Ludvik B, Zacherl J, Prager G: Inadequate Weight Loss vs Secondary Weight Regain: Laparoscopic Conversion from Gastric Banding to Roux-en-Y Gastric Bypass. *Obes Surg* 18(11):1381-6, 2008
83. Brema I, Hatunic M, Finucane F, Burns N, Nolan JJ, Haider D, Wolzt M, Ludvik B: Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. *Diabetes Obes Metab* 10(7):600-2, 2008
84. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, Zlabinger GJ, Stulnig TM: CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. *J Clin Endocrinol Metab* 93(8):3215-21, 2008
85. Maier C, Riedl M, Vila G, Nowotny P, Wolzt M, Clodi M, Ludvik B, Luger A: Cholinergic regulation of ghrelin and PYY release may be impaired in obesity. *Diabetes* 57(9):2332-40, 2008
86. Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, Karnieli E, Assalia A, Prager R, Prager: Improvement in glycemic control by gastric electrical stimulation (TANTALUS(TM)) in overweight subjects with type 2 diabetes. *G.Surg Endosc*, 2008, [Epub ahead of print]
87. Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, Prager G, Ludvik B, Clodi M, Luger A: Plasma MR-proADM Correlates to BMI and Decreases in Relation to Leptin After Gastric Bypass Surgery. *Obesity (Silver Spring)*, 2009, [Epub ahead of print]
88. Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B: The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART). *Horm Metab Res*, 2009, [Epub ahead of print]

## CHAPTERS IN BOOKS

1. Weissel M, Punzengruber C, Hartter E, Burghuber OC, **Ludvik B**, Woloszczuk W: Effect of treatment with L-thyroxine on plasma ANP levels in athyreotic patients: indirect evidence for the necessity of adequate thyroid hormone levels to maintain normal ANP levels. In *Advances in atrial peptide research*. Vol 2 ed. Brenner BM, Saragh JH, Eds. 1988, p. 293-297
2. Graf H, Watzinger U, **Ludvik B**, Wagner A, Höcker B, Zweymüller KK: Eigenblutspende unter Erythropoietin - ein neues Konzept für elektive orthopädische Eingriffe. In *10 Jahre Zweymüller Hüftendoprothese*. Zweymüller KK, Ed. 1990, p. 77-81

3. Kautzky-Willer A, Capek M, Pacini G, **Ludvik B**, Prager R: Insulin secretion, insulin sensitivity and hepatic insulin extraction in essential hypertension. In Current Topics in Diabetes Research. Karger Verlag, 1993, p. 250-253
4. **Ludvik B**: Adipositas – Diagnostik und Therapie. In Ernährungsmedizin. Widhalm K, Diallo-Ginstl E, Eds. ÖAK 2000, 334-346
5. **Ludvik B**: Konservative Therapie der morbiden Adipositas. In Morbide Adipositas – Klinik und Therapie. Hell E, Miller K, Eds. Ecomed 2000, 20-25
6. **Ludvik B**: Sekundäre Diabetesformen. In Diabetes in der Praxis. Waldhaeusl W, Gries FA, Scherbaum W, Eds. Springer Verlag Berlin 2004
7. **Ludvik B**: Diabetes mellitus: ein progerones Krankheitsbild. Therapie, Prävention und Einfluss von Lifestyle. In Angewandte Anti-Aging-Medizin. Gasser R (Hg). Verlagshaus der Ärzte 2004

### **BOOKS**

1. **Ludvik B** (Ed.): Risikofaktor Diabetes – Konzepte für ein Langzeitproblem. Uni-Med-Verlag Bremen, 1.Aufl. 2004 [ISBN: 3-89599-824-9]
2. **Ludvik B**, Toplak H: Medikamentöse Therapie der Adipositas. Springer Verlag Wien, 1.Aufl. 2006 [ISBN: 3-211-83815-5]
3. Mihaljevic K, Feffer S, **Ludvik B**: Essen mit Spass + Aktivsein mit Mass. So entkommen Sie dem Metabolischen Syndrom, Verlagshaus der Ärzte, 1. Aufl. 2006 [ISBN: 3-901488-75-8]
4. Pfeiffer A, **Ludvik B**, Kinzl JF: Für immer dünn. [Audio CD - Hörbuch], Galila Hörbuchverlag, 1.Aufl. 2006 [ISBN: 3902533013]
5. Prager R, Abrahamian H, Kautzky-Willer A, **Ludvik B**, Schütz-Fuhrmann I, Weitgasser R: Diabetesmanagement mit Insulinanaloga. UNI-MED Verlag AG, 1. Auflage, 2008 [ISBN 978-3-89599-919-2]